IP Library Granted Patent US 10,118,929
Granted Patent B2
US 10,118,929 · App. 15/498,736 · Granted Nov 6, 2018

Nonanoic and decanoic acid derivatives and uses thereof

Inventors: Takeru Furuya (Cambridge, MA); Ben C. Askew (Marshfield, MA)
Assignee: SciFluor Life Sciences, Inc.
C07D487/04C07D233/36C07D401/06C07D401/12C07D403/12C07D413/12C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,118,929
App. No.
15/498,736
Granted
Nov 6, 2018
Kind
B2
Abstract

The present disclosure relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present disclosure also relates to pharmaceutical compositions containing the fluorinated compounds of the disclosure, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Claims (10)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt or solvate thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient.

3. A method of treating a disease or condition mediated by an αv integrin in a subject, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof.

4. The compound of claim 1 , being

or a pharmaceutically acceptable salt or solvate thereof.

5. The compound of claim 1 , being

or a pharmaceutically acceptable salt or solvate thereof.

6. The compound of claim 1 , being

or a pharmaceutically acceptable salt or solvate thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2026
From: OCUTERRA THERAPEUTICS, INC. (FORMERLY KNOWN AS SCIFLUOR LIFE SCIENCES, INC.)
To: FELIQS CORPORATION
Reel/Frame 073443/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2017
From: FURUYA, TAKERU; ASKEW, BEN C.
To: SCIFLUOR LIFE SCIENCES, INC.
Reel/Frame 042211/0279 →
Continuity (2)
Provisional Application 62328187 · Apr 27, 2016
Related Publication 20170313708A1 · Nov 2, 2017